...

Treatment-Resistant Depression:

Why Standard Medications Fail and What Comes Next

When a first or second antidepressant fails to provide relief, the immediate assumption is often that the condition is untreatable. It isn’t. This specific clinical bottleneck is known as Treatment-Resistant Depression (TRD). It is a highly documented medical reality with distinct biological causes—and it means your brain requires a different therapeutic mechanism, not just a higher dose of the same daily medication

This naturally raises important questions:

What Is Treatment-Resistant Depression?

man in his chair, showing signs of depression or anxiety

The Clinical Definition

The Limits of the Trial-and-Error Method

Statistically, finding the right daily antidepressant is a process of diminishing returns. The benchmark data comes from the National Institutes of Health STAR*D trial—the largest prospective study on depression ever conducted.

The study tracked a clear pattern: while roughly one-third of patients found relief with their first medication, the success rate dropped sharply with every subsequent attempt. After two unsuccessful medication trials, the likelihood of a third standard antidepressant working drops below 15%.

This data shifted modern psychiatry away from endless medication switching. If you have tried two or more daily prescriptions without success, the clinical focus must pivot toward advanced options like IV ketamine therapy, which targets completely different neural pathways to bypass the serotonin bottleneck entirely.

How Common Is It?

This isn’t a rare or unusual situation. Nearly 30% of individuals with major depressive disorder are classified as treatment-resistant. That means roughly one in three people being treated for depression will, at some point, find themselves in this exact spot — having done everything asked of them, and still not feeling better.

It’s worth noting that the field continues to debate the finer points of this definition. Some researchers question whether the current criteria fully capture the lived experience of resistant depression, and there’s ongoing discussion about whether a lack of response to psychotherapy should factor into the definition as well. What matters most for someone living with this condition isn’t the precise clinical label — it’s understanding that persistent depression despite treatment is a recognized, studied, and increasingly treatable medical reality.

Why Do Standard Antidepressants Fail for So Many People?

Depression Is Not One-Size-Fits-All

Traditional antidepressants (like SSRIs and SNRIs) operate on a single primary theory: that adjusting brain chemistry via neurotransmitters like serotonin will lift depressive symptoms.

The issue is that depression isn’t uniform. For many individuals, the underlying driver isn’t a serotonin deficit at all—it is rooted in chronic brain inflammation, neural connectivity gaps, or stress-hormone deregulation. If a medication is built for a biological pathway your body isn’t using, it cannot produce a clinical response.

The Slow Start Becomes a Costly Delay

Even when a medication is well-matched to a person’s biology, conventional antidepressants typically take four to eight weeks to produce a noticeable effect and that’s only after the right dose has been found. If the first medication doesn’t work, the process starts over with a new one. For someone in crisis, that trial-and-error timeline can mean months or years of continued suffering while searching for the right fit.

Research Has Tracked This Problem Directly

One of the most influential studies on this exact issue, the STAR*D trial, followed patients through multiple rounds of antidepressant treatment to see how many achieved remission at each stage. The pattern was sobering: with each failed medication trial, the odds of the next one working went down, and that decline became especially steep after the second unsuccessful attempt. For the patients who did eventually reach remission, staying well became the next challenge, since relapse risk remained a concern even after symptoms improved.

This research helped shift the conversation in psychiatry. Rather than assuming every patient would eventually respond if enough medications were tried, it became clear that a meaningful subset of people needed a fundamentally different therapeutic approach not just another pill in the same category.

What Comes Next: Modern Options Beyond the Standard Antidepressant

The good news is that “resistant” doesn’t mean “untreatable.” Several approaches have demonstrated real effectiveness for people who haven’t responded to conventional antidepressants.

doctor and the patient
doctor and the patient

Ketamine and Esketamine Therapy

Ketamine works on a completely different brain pathway than traditional antidepressants. Instead of targeting serotonin or norepinephrine directly, it acts on the brain’s glutamate system and is believed to promote neuroplasticity essentially helping the brain form new neural connections and break out of the rigid, self-reinforcing patterns associated with chronic depression. Because of this different mechanism, ketamine can help some people who have not responded to two, three, or more standard medications.

One of the most clinically meaningful aspects of ketamine treatment is its speed. While SSRIs may take weeks to show any benefit, ketamine has been shown in numerous studies to rapidly ease depressive symptoms and reduce suicidal thinking, often within hours or days of a single infusion, with effects that can last roughly a week per session. This is part of why ketamine has become an important option specifically for people who have already been through the standard medication process without success.

Electroconvulsive Therapy (ECT)

ECT remains one of the most effective treatments available for severe, treatment-resistant depression. While it carries a reputation shaped by outdated portrayals, modern ECT is performed under anesthesia with careful monitoring and has a strong track record for patients who haven’t responded to medication.

Repetitive Transcranial Magnetic Stimulation (rTMS)

rTMS uses magnetic pulses to stimulate specific regions of the brain associated with mood regulation. It’s non-invasive, doesn’t require anesthesia, and has become a well-established option for treatment-resistant cases, often used in a series of sessions over several weeks.

Adjunctive Medication Strategies

Sometimes the answer isn’t switching medications entirely but adding a second agent such as an atypical antipsychotic or a mood stabilizer alongside an existing antidepressant. This combination approach can sometimes produce a response that neither medication achieved on its own.

How to Know If Ketamine Therapy Might Be Right for You

Ketamine therapy is generally considered for adults who have tried at least two antidepressant medications without adequate relief, and who are looking for an evidence-based option with a different mechanism of action. It’s typically administered in a controlled clinical setting with monitoring throughout the session, since dosing, safety screening, and supervision all matter for getting a good outcome.

If you’ve been cycling through medications without the relief you were hoping for, that experience doesn’t mean treatment has failed it may simply mean it’s time to explore an approach built around a different understanding of how depression takes hold in the brain. A free consultation is the most direct way to find out whether you’re a candidate

Frequently Asked Question

Yes, when administered in a controlled clinical environment under direct medical supervision. While ketamine is a powerful FDA-approved anesthetic, we use precise, low “sub-anesthetic” doses for mental health recovery. Because it does not cause respiratory depression or drop your blood pressure like standard anesthetics, it has an excellent safety profile.

Most patients experience a temporary, mild dissociation (a feeling of being light or slightly detached from your physical body) and temporary changes in visual perception. You may also feel a brief increase in heart rate or blood pressure. Mild nausea or slight tiredness can occur, but these effects wear off quickly—typically within 15 to 20 minutes after the infusion ends.

Your safety is our priority. At the Ketamine Center of CT, we do not use loud, squeezing arm cuffs that disrupt your treatment every few minutes. Instead, we utilize advanced, continuous Caretaker® wireless monitoring technology. Dr. Gino Ang and our trained clinical team track your vitals in real time throughout the entire session so you are never left alone.

Ketamine is fully FDA-approved as a surgical anesthetic and has been safely used since 1970. Its use for depression is considered an “off-label” application, which is a common and standard practice in modern medicine when a drug is backed by extensive clinical research. However, the nasal spray version, Spravato® (esketamine), is fully FDA-approved specifically for treatment-resistant depression.

Is ketamine available at Ketamine Center of Connecticut?

KetamineCenterOffice

Mandatory Patient Safety & Driving Protocol:

 

Because ketamine is a potent anesthetic that temporarily impacts your reflexes, motor coordination, and visual perception, you must strictly follow these safety rules:

  • Pre-Arranged Transport Required: You are explicitly prohibited from driving yourself home after an infusion. You must arrange for a trusted friend, family member, or rideshare service to pick you up from the clinic.

  • The 24-Hour Rule: Do not drive, operate heavy machinery, or make major legal/financial decisions for the remainder of the treatment day. You may safely resume driving the following calendar day only after a full night of restful sleep.

  • Strictly In-Office: Use of ketamine outside our controlled clinical environment is unsafe and strictly prohibited.

If you are experiencing symptoms of depression and want to explore treatment safely, please contact us to schedule a consultation at our Milford or Westport clinic. All care is personalized to ensure absolute clinical efficacy and patient safety.

Ketamine treatment is available at our two Connecticut locations:

232 Boston Post Rd Suite 13, Milford, CT 06460
 1720 Post Rd E Suite 222, Westport, CT 06880

Treatments are strictly supervised by a board-certified physician, Dr. Gino Ang. Ketamine is prescribed only for adults with major depressive disorder who have not responded adequately to at least two different antidepressants. All treatment sessions are conducted in a controlled clinical environment, and Ketamine is administered under the physician’s direct supervision.

Patients must follow strict protocols:

  • Ketamine is prescribed and monitored only by a qualified physician.
  • Treatment is delivered in-office with continuous medical oversight.
  • Use of ketamine outside this controlled setting is unsafe and not permitted.

If you are experiencing symptoms of depression and want to explore ketamine treatment, please contact us to schedule a consultation at our Milford or Westport clinic. All care is personalized to ensure safety, efficacy, and adherence to clinical guidelines.

Doctor-Ang

Dr. Gino Ang MD 

Board-Certified Anesthesiologist 

Medical Review & Disclaimer

This content was reviewed for medical accuracy by Dr. Gino of the Ketamine Center of CT. This information is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Use of this site does not establish a doctor-patient relationship.

Take the Next Step Toward Relief

If you’ve been searching for a treatment that offers real, rapid, and lasting improvement even when other options haven’t helped ketamine therapy may be the answer. Our team is here to guide you with compassion, expertise, and personalized care every step of the way.
Book A Call
Scroll to Top
Seraphinite AcceleratorOptimized by Seraphinite Accelerator
Turns on site high speed to be attractive for people and search engines.